Evidence map›Paper›PMID 30941644›Full record

ArticleMolecular biology reports2019

Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer.

Dorra BenAyed-Guerfali, Emna Dabbèche-Bouricha, Wajdi Ayadi, Fatma Trifa, Slim Charfi, Abdelmajid Khabir, Tahia Sellami-Boudawara, Raja Mokdad-Gargouri

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. The Role of the Fox Gene in Breast Cancer Progression.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dorra BenAyed-GuerfaliCenter of Biotechnology of Sfax, University of Sfax, Sidi Mansour Street Km 6, BP 1177, 3038, Sfax, Tunisia.
Emna Dabbèche-BourichaCenter of Biotechnology of Sfax, University of Sfax, Sidi Mansour Street Km 6, BP 1177, 3038, Sfax, Tunisia.
Wajdi AyadiCenter of Biotechnology of Sfax, University of Sfax, Sidi Mansour Street Km 6, BP 1177, 3038, Sfax, Tunisia.
Fatma TrifaInstitute of Biotechnology of Monastir, BP 223, 5000, Monastir, Tunisia.
Slim CharfiDepartment of Anatomo-pathology, Habib Bourguiba Hospital, Sfax, Tunisia.
Abdelmajid KhabirDepartment of Anatomo-pathology, Habib Bourguiba Hospital, Medenin, Tunisia.
Tahia Sellami-BoudawaraDepartment of Anatomo-pathology, Habib Bourguiba Hospital, Sfax, Tunisia.
Raja Mokdad-GargouriCenter of Biotechnology of Sfax, University of Sfax, Sidi Mansour Street Km 6, BP 1177, 3038, Sfax, Tunisia. raja.gargouri@cbs.rnrt.tn.ORCID http://orcid.org/0000-0003-1319-0061

Funding

Ministry of Higher Education and Scientific Research LR15CBS02
6 · The paper itself

Abstract

The transcription factor FOXA1 (forkhead box A1) plays key roles in tumor development and progression. In the present study, we analyzed the expression of FOXA1 in 52 breast tumors and 10 normal tissues, and investigated the relationship between FOXA1 and two EMT markers, namely Twist1 and E-cadherin by RT-PCR and IHC respectively. The expression level of FOXA1 was higher in tumor compared to normal tissues but the difference was not statistically significant (P = 0.138). FOXA1 expression correlated with less aggressive behavior as SBR grade I (P = 0.04), small tumors size (P = 0.05), and longer survival (P = 0.001). Furthermore, estrogen and progesterone positive tumors exhibit high level of FOXA1 (P = 0.002 and P = 0.038 respectively). Survival analysis showed that patients with ER positive/FOXA1 positive (P log rank = 0.001), PR positive/FOXA1 positive (P log rank = 0.044) and HER-2 negative/FOXA1 positive (P log rank = 0.002) tumors have a significant prolonged overall survival. On the other hand, the expression of E-cadherin positively correlated with FOXA1 (P = 0.028), whereas negative association was seen between the expression of Twist1 and FOXA1 (P = 0.016). Kaplan-Meier plots showed that patients with Twist1negative/FOXA1positive tumors have a significant prolonged overall survival (P log rank = 0.001) and FOXA1 appeared as independent predictors of patient survival in multivariate analyses. Overall, our results indicate that FOXA1 could be a useful biomarker to predict prognosis in breast cancer patients.

Indexed as

AdultAgedAntigens, CDBiomarkers, TumorBreastBreast NeoplasmsCadherinsFemaleHepatocyte Nuclear Factor 3-alphaHumansMiddle AgedNeoplasm StagingNuclear ProteinsPrognosisReceptors, EstrogenReceptors, ProgesteroneAntigens, CDBiomarkers, TumorCadherinsCDH1 protein, humanFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaNuclear ProteinsReceptors, EstrogenReceptors, ProgesteroneTWIST1 protein, humanTwist-Related Protein 1BiomarkerBreast cancerEpithelial to mesenchymal transitionImmunohistochemistry

Identifiers

PMID30941644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.